|Articles|May 9, 2013

Nexera X2 — X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nex-era X2 UHPLC system targets routine analysis and applications in highly regulated environ-ments demanding complex system setups

Nexera X2 – X-ceptional insights

Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new

Nexera X2

UHPLC system targets routine analysis and applications in highly regulated environ-ments demanding complex system setups.

System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.

Stability
Stability in gradient use has been improved by pump side modifications. Further-more, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific applications, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method trans-fer.

Sensitivity
The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applica-tions using a capillary cell with low dispersion. Total reflection and a high en-ergy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.

For more information please visit www.shimadzu.eu.

Related to this article

FDA
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.